Here's Why CRISPR Therapeutics Shares Jumped 13.8% in June

Shares of CRISPR Therapeutics (NASDAQ: CRSP) jumped 13.8% in June, according to data provided by S&P Global Market Intelligence, after the biotech released data at two different medical meetings during the month.

First, CRISPR and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) presented additional data from its clinical trials testing their gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease.

Both patients with TDT haven't required transfusions since they received their therapies five and 15 months ago. That's pretty impressive, considering they previously required 61 units and 34 units of red blood cells per year, respectively, in the two years before treatment.

Continue reading

Source Fool.com